Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis

Multiple sclerosis (MS) is the most frequent chronic inflammatory disease of the CNS, and imposes major burdens on young lives. Great progress has been made in understanding and moderating the acute inflammatory components of MS, but the pathophysiological mechanisms of the concomitant neurodegeneration—which causes irreversible disability—are still not understood. Chronic inflammatory processes that continuously disturb neuroaxonal homeostasis drive neurodegeneration, so the clinical outcome probably depends on the balance of stressor load (inflammation) and any remaining capacity for neuronal self-protection. Hence, suitable drugs that promote the latter state are sorely needed. With the aim of identifying potential novel therapeutic targets in MS, we review research on the pathological mechanisms of neuroaxonal dysfunction and injury, such as altered ion channel activity, and the endogenous neuroprotective pathways that counteract oxidative stress and mitochondrial dysfunction. We focus on mechanisms inherent to neurons and their axons, which are separable from those acting on inflammatory responses and might, therefore, represent bona fide neuroprotective drug targets with the capability to halt MS progression.

[1]  S. Love,et al.  Elevated Activity and Microglial Expression of Myeloperoxidase in Demyelinated Cerebral Cortex in Multiple Sclerosis , 2008, Brain pathology.

[2]  David H. Miller,et al.  Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. , 2002, Brain : a journal of neurology.

[3]  R. Reynolds,et al.  Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. , 2012, Brain : a journal of neurology.

[4]  P. Hanson,et al.  Edinburgh Research Explorer Mitochondrial Changes within Axons in Multiple Sclerosis Mitochondrial Changes within Axons in Multiple Sclerosis , 2022 .

[5]  H. Bading,et al.  Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders , 2010, Nature Reviews Neuroscience.

[6]  Richard Reynolds,et al.  Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis , 2011, Annals of neurology.

[7]  D. Centonze,et al.  Inflammation Triggers Synaptic Alteration and Degeneration in Experimental Autoimmune Encephalomyelitis , 2009, The Journal of Neuroscience.

[8]  A. Thompson,et al.  Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. , 2003, Brain : a journal of neurology.

[9]  P. Elliott,et al.  Oral Resveratrol Reduces Neuronal Damage in a Model of Multiple Sclerosis , 2010, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[10]  W Craelius,et al.  Iron deposits surrounding multiple sclerosis plaques. , 1982, Archives of pathology & laboratory medicine.

[11]  H. Weiner A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis , 2008, Journal of Neurology.

[12]  Alessandro Martorana,et al.  Exercise attenuates the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitis , 2009, Neurobiology of Disease.

[13]  M. Ramanathan,et al.  Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. , 2007, Human molecular genetics.

[14]  D. Pitt,et al.  Glutamate excitotoxicity in a model of multiple sclerosis , 2000, Nature Medicine.

[15]  Pierre J. Magistretti,et al.  Oligodendroglia metabolically support axons and contribute to neurodegeneration , 2012, Nature.

[16]  A. Echaniz-Laguna,et al.  POLG1 variations presenting as multiple sclerosis. , 2010, Archives of neurology.

[17]  F. Abboud,et al.  Extracellular acidosis increases neuronal cell calcium by activating acid-sensing ion channel 1a. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  P. Gustafson,et al.  Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. , 2012, JAMA.

[19]  Pardis C Sabeti,et al.  Population genetic study of the brain-derived neurotrophic factor (BDNF) gene , 2009, Molecular Psychiatry.

[20]  Gwo-hsiao Chen,et al.  Loss of Na+ channel β2 subunits is neuroprotective in a mouse model of multiple sclerosis , 2009, Molecular and Cellular Neuroscience.

[21]  B. Scheithauer,et al.  Inflammatory cortical demyelination in early multiple sclerosis. , 2011, The New England journal of medicine.

[22]  R. Rudick,et al.  Neurological disability correlates with spinal cord axonal loss and reduced N‐acetyl aspartate in chronic multiple sclerosis patients , 2000, Annals of neurology.

[23]  D. Turnbull,et al.  Increased mitochondrial content in remyelinated axons: implications for multiple sclerosis. , 2011, Brain : a journal of neurology.

[24]  S. Zamvil,et al.  K+ channel alterations in the progression of experimental autoimmune encephalomyelitis , 2012, Neurobiology of Disease.

[25]  David H. Miller,et al.  Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial , 2009, The Lancet Neurology.

[26]  D. Centonze,et al.  Cannabinoid CB1 receptors regulate neuronal TNF-α effects in experimental autoimmune encephalomyelitis , 2011, Brain, Behavior, and Immunity.

[27]  X. Montalban,et al.  The value of animal models for drug development in multiple sclerosis. , 2006, Brain : a journal of neurology.

[28]  S. Waxman,et al.  Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine , 2007, Annals of neurology.

[29]  R. Reynolds,et al.  Molecular Changes in Normal Appearing White Matter in Multiple Sclerosis are Characteristic of Neuroprotective Mechanisms Against Hypoxic Insult , 2003, Brain pathology.

[30]  Hans Lassmann,et al.  The relation between inflammation and neurodegeneration in multiple sclerosis brains , 2009, Brain : a journal of neurology.

[31]  Hans Lassmann,et al.  Widespread Demyelination in the Cerebellar Cortex in Multiple Sclerosis , 2007, Brain pathology.

[32]  Shyam Biswal,et al.  Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. , 2007, Annual review of pharmacology and toxicology.

[33]  A. Salinaro,et al.  Redox regulation of cellular stress response in multiple sclerosis. , 2011, Biochemical pharmacology.

[34]  H. Lassmann,et al.  Explorer NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury , 2012 .

[35]  G. Ketels,et al.  Effects of exercise on fitness and cognition in progressive MS: a randomized, controlled pilot trial , 2014, Multiple sclerosis.

[36]  Hans Lassmann,et al.  Activated Human T Cells, B Cells, and Monocytes Produce Brain-derived Neurotrophic Factor In Vitro and in Inflammatory Brain Lesions: A Neuroprotective Role of Inflammation? , 1999, The Journal of experimental medicine.

[37]  A. Minagar,et al.  Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis , 2011 .

[38]  R. Sergott Imaging correlates of decreased axonal Na+/K+ ATPase in chronic multiple sclerosis lesions , 2008 .

[39]  A J Thompson,et al.  Brain atrophy in clinically early relapsing-remitting multiple sclerosis. , 2002, Brain : a journal of neurology.

[40]  Xavier Golay,et al.  Sodium accumulation is associated with disability and a progressive course in multiple sclerosis. , 2013, Brain : a journal of neurology.

[41]  E. Sribnick,et al.  Upregulation of calpain correlates with increased neurodegeneration in acute experimental auto‐immune encephalomyelitis , 2005, Journal of neuroscience research.

[42]  E. Melamed,et al.  Mice overexpressing Bcl-2 in their neurons are resistant to myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) , 2000, Journal of Molecular Neuroscience.

[43]  T. Olsson,et al.  Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab , 2011, Annals of neurology.

[44]  Mary T. Brinkoetter,et al.  A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis , 2011, Nature Medicine.

[45]  R. Reynolds,et al.  Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. , 2011, Brain : a journal of neurology.

[46]  R. Gold,et al.  Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration , 2006, Clinical and experimental immunology.

[47]  Jörg R. P. Geiger,et al.  Energy-Efficient Action Potentials in Hippocampal Mossy Fibers , 2009, Science.

[48]  Bruce P. Bean,et al.  Sodium Entry during Action Potentials of Mammalian Neurons: Incomplete Inactivation and Reduced Metabolic Efficiency in Fast-Spiking Neurons , 2009, Neuron.

[49]  D. Bourdette,et al.  Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis , 2007, Proceedings of the National Academy of Sciences.

[50]  S. Confort-Gouny,et al.  Block of neural Kv1.1 potassium channels for neuroinflammatory disease therapy , 2006, Annals of neurology.

[51]  K. Selmaj,et al.  Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. , 2010, Brain : a journal of neurology.

[52]  H. Lassmann,et al.  Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis. , 2001, Brain : a journal of neurology.

[53]  G. Comi,et al.  MGAT5 alters the severity of multiple sclerosis , 2010, Journal of Neuroimmunology.

[54]  S. Elkabes,et al.  Beneficial effect of erythropoietin on experimental allergic encephalomyelitis , 2004, Annals of neurology.

[55]  K. Jellinger,et al.  Preferential Loss of Myelin‐Associated Glycoprotein Reflects Hypoxia‐Like White Matter Damage in Stroke and Inflammatory Brain Diseases , 2003, Journal of neuropathology and experimental neurology.

[56]  H. D. de Vries,et al.  Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. , 2008, Free radical biology & medicine.

[57]  D. Sparks,et al.  Microglial dystrophy in the aged and Alzheimer's disease brain is associated with ferritin immunoreactivity , 2008, Glia.

[58]  O. Pongs,et al.  TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis , 2012, Nature Medicine.

[59]  A. Redensek,et al.  Ceruloplasmin Protects Injured Spinal Cord from Iron-Mediated Oxidative Damage , 2008, The Journal of Neuroscience.

[60]  Simon Hametner,et al.  Disease-specific molecular events in cortical multiple sclerosis lesions , 2013, Brain : a journal of neurology.

[61]  H. Lassmann,et al.  CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation , 2002, Nature Medicine.

[62]  G. Krissansen,et al.  Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis. , 2004, Brain : a journal of neurology.

[63]  Peter K Stys,et al.  Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis , 2009, The Lancet Neurology.

[64]  E. Brand-Schieber,et al.  Calcium channel blockers ameliorate disease in a mouse model of multiple sclerosis , 2004, Experimental Neurology.

[65]  M. Daumer,et al.  Early relapses, onset of progression, and late outcome in multiple sclerosis. , 2013, JAMA neurology.

[66]  C. Lucchinetti,et al.  Pathology of demyelinating diseases. , 2012, Annual review of pathology.

[67]  Martin Röcken,et al.  Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells , 2012 .

[68]  A. Blight,et al.  Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis , 2011, Current medical research and opinion.

[69]  DelindaA . Johnson,et al.  The absence of the pro-antioxidant transcription factor Nrf2 exacerbates experimental autoimmune encephalomyelitis. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[70]  C. Ledent,et al.  Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis , 2008, Journal of Neuroimmunology.

[71]  T. Bíró,et al.  Transient receptor potential channels as therapeutic targets , 2011, Nature Reviews Drug Discovery.

[72]  L. Turski,et al.  Autoimmune encephalomyelitis ameliorated by AMPA antagonists , 2000, Nature Medicine.

[73]  L. Fugger,et al.  Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system , 2007, Nature Medicine.

[74]  W. Brück,et al.  Molecular Changes in White Matter Adjacent to an Active Demyelinating Lesion in Early Multiple Sclerosis , 2009, Brain pathology.

[75]  P. Stys,et al.  Mechanisms of axonal injury: internodal nanocomplexes and calcium deregulation. , 2010, Trends in molecular medicine.

[76]  R. Rudick,et al.  Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients , 2006, Annals of neurology.

[77]  J. Kemp,et al.  NMDA receptor pathways as drug targets , 2002, Nature Neuroscience.

[78]  H. Weiner,et al.  Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. , 2008, The Journal of clinical investigation.

[79]  D. Bechtold,et al.  Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis. , 2013, Brain : a journal of neurology.

[80]  H. Broxmeyer Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration , 2013, The Journal of experimental medicine.

[81]  D. Bechtold,et al.  Axonal protection achieved in a model of multiple sclerosis using lamotrigine , 2006, Journal of Neurology.

[82]  D. Bechtold,et al.  Axonal protection using flecainide in experimental autoimmune encephalomyelitis , 2004, Annals of neurology.

[83]  George C. Ebers,et al.  The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability , 2010, Brain : a journal of neurology.

[84]  J. Dunn,et al.  Susceptibility-weighted imaging in the experimental autoimmune encephalomyelitis model of multiple sclerosis indicates elevated deoxyhemoglobin, iron deposition and demyelination , 2013, Multiple sclerosis.

[85]  J. Newcombe,et al.  Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide production and neurodegeneration , 2012, The Journal of experimental medicine.

[86]  John A. Wemmie,et al.  Acid-sensing ion channels in pain and disease , 2013, Nature Reviews Neuroscience.

[87]  Jia Newcombe,et al.  Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[88]  Christine Stadelmann,et al.  Wallerian Degeneration: A Major Component of Early Axonal Pathology in Multiple Sclerosis , 2010, Brain pathology.

[89]  J. M. Ritchie,et al.  Molecular dissection of the myelinated axon , 1993, Annals of neurology.

[90]  M. Jenkinson,et al.  Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride. , 2013, Brain : a journal of neurology.

[91]  W. Brück,et al.  Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. , 2000, Brain : a journal of neurology.

[92]  A. Verma,et al.  Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study , 2008 .

[93]  D. Attwell,et al.  Updated Energy Budgets for Neural Computation in the Neocortex and Cerebellum , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[94]  Michael R. Johnson,et al.  Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. , 2009, Human molecular genetics.

[95]  P. D. Jager,et al.  Genome-wide association study of severity in multiple sclerosis , 2011, Genes and Immunity.

[96]  Martin Daumer,et al.  Onset of secondary progressive phase and long-term evolution of multiple sclerosis , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[97]  A. Hodgkin The optimum density of sodium channels in an unmyelinated nerve. , 1975, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[98]  Hellmut Merkle,et al.  Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla. , 2011, Brain : a journal of neurology.

[99]  D. Wallace,et al.  Mitochondrial energetics and therapeutics. , 2010, Annual review of pathology.

[100]  Jeremy Hobart,et al.  Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial , 2013, The Lancet Neurology.

[101]  D. Centonze,et al.  Abnormal NMDA receptor function exacerbates experimental autoimmune encephalomyelitis , 2013, British journal of pharmacology.

[102]  V. Gallai†,et al.  Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid. , 2003, Archives of neurology.

[103]  W. Brück,et al.  Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. , 2011, Brain : a journal of neurology.

[104]  R. Gold,et al.  Central nervous system rather than immune cell-derived BDNF mediates axonal protective effects early in autoimmune demyelination , 2011, Acta Neuropathologica.

[105]  Christian Langkammer,et al.  Iron and Neurodegeneration in Multiple Sclerosis , 2011, Multiple sclerosis international.

[106]  Simon Hametner,et al.  Iron and neurodegeneration in the multiple sclerosis brain , 2013, Annals of neurology.

[107]  Frederik Barkhof,et al.  Grey matter pathology in multiple sclerosis , 2008, The Lancet Neurology.

[108]  Axel Petzold,et al.  Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis , 2010, The Lancet Neurology.

[109]  H. Wiendl,et al.  The TASK1 channel inhibitor A293 shows efficacy in a mouse model of multiple sclerosis , 2012, Experimental Neurology.

[110]  C. Bolton,et al.  Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-D-aspartate receptor antagonist memantine. , 2002, The Journal of pharmacology and experimental therapeutics.

[111]  Pradeep J. Nathan,et al.  BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases , 2013, Nature Reviews Neuroscience.

[112]  H. Lassmann,et al.  Oxidative damage in multiple sclerosis lesions , 2011, Brain : a journal of neurology.

[113]  M. Tuszynski,et al.  Potential therapeutic uses of BDNF in neurological and psychiatric disorders , 2011, Nature Reviews Drug Discovery.

[114]  Pico Caroni,et al.  Selective Neuronal Vulnerability in Neurodegenerative Diseases: from Stressor Thresholds to Degeneration , 2011, Neuron.

[115]  C. Ledent,et al.  Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells , 2007, Nature Medicine.

[116]  A. Lo,et al.  Sodium channels contribute to microglia/macrophage activation and function in EAE and MS , 2005, Glia.

[117]  G. Comi,et al.  Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. , 2012, The American journal of pathology.

[118]  Keith Baar,et al.  Resveratrol Ameliorates Aging-Related Metabolic Phenotypes by Inhibiting cAMP Phosphodiesterases , 2012, Cell.

[119]  Kenneth J. Smith,et al.  Electrically active axons degenerate when exposed to nitric oxide , 2001, Annals of neurology.

[120]  J. Newcombe,et al.  Glutamate Receptor Expression in Multiple Sclerosis Lesions , 2008, Brain pathology.

[121]  Y. Zhang,et al.  Distinct role of nitric oxide and peroxynitrite in mediating oligodendrocyte toxicity in culture and in experimental autoimmune encephalomyelitis , 2011, Neuroscience.

[122]  L. Fugger,et al.  Therapies for multiple sclerosis: translational achievements and outstanding needs. , 2013, Trends in molecular medicine.

[123]  R. Mutani,et al.  Altered Glutamate Reuptake in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis Cortex: Correlation With Microglia Infiltration, Demyelination, and Neuronal and Synaptic Damage , 2007, Journal of neuropathology and experimental neurology.

[124]  M. Eder,et al.  CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity , 2003, Science.

[125]  M. Cuénod,et al.  Murine brain macrophages induce NMDA receptor mediated neurotoxicity in vitro by secreting glutamate , 1991, Neuroscience Letters.

[126]  B. Trapp,et al.  Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions , 2001, Annals of neurology.

[127]  P. Fontoura,et al.  Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. , 2007, The Journal of clinical investigation.

[128]  Arthur F. Kramer,et al.  Aerobic fitness is associated with gray matter volume and white matter integrity in multiple sclerosis , 2010, Brain Research.

[129]  M. Ramanathan,et al.  Effect of Met66 allele of the BDNF rs6265 SNP on regional gray matter volumes in patients with multiple sclerosis: A voxel-based morphometry study. , 2011, Pathophysiology : the official journal of the International Society for Pathophysiology.

[130]  A. Lo,et al.  Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. , 2003, Journal of neurophysiology.

[131]  Alistair Mathie,et al.  Therapeutic potential of neuronal two-pore domain potassium-channel modulators. , 2007, Current opinion in investigational drugs.

[132]  M. Esiri,et al.  Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model. , 2011, Brain : a journal of neurology.

[133]  P. Launay,et al.  Physiological roles of the TRPM4 channel extracted from background currents. , 2010, Physiology.

[134]  B. Seitz,et al.  A randomized, double‐blind, phase 2 study of erythropoietin in optic neuritis , 2012, Annals of neurology.

[135]  L. Kappos,et al.  Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis , 2011, Neurology.

[136]  David H. Miller,et al.  Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial , 2010, The Lancet Neurology.

[137]  David H. Miller,et al.  Imaging outcomes for neuroprotection and repair in multiple sclerosis trials , 2009, Nature Reviews Neurology.

[138]  Hans Lassmann,et al.  Progressive multiple sclerosis: pathology and pathogenesis , 2012, Nature Reviews Neurology.

[139]  M. Esiri,et al.  The contribution of demyelination to axonal loss in multiple sclerosis. , 2006, Brain : a journal of neurology.

[140]  Axel Petzold Optical Coherence Tomography in Multiple Sclerosis , 2016 .

[141]  S. Khoury,et al.  Protecting Axonal Degeneration by Increasing Nicotinamide Adenine Dinucleotide Levels in Experimental Autoimmune Encephalomyelitis Models , 2006, The Journal of Neuroscience.

[142]  F. Mokhtarian,et al.  Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encephalomyelitis , 2008, Brain Research.

[143]  R. Bronson,et al.  Elevated neuronal expression of CD200 protects Wlds mice from inflammation-mediated neurodegeneration. , 2007, The American journal of pathology.

[144]  Frauke Zipp,et al.  Neuronal Damage in Autoimmune Neuroinflammation Mediated by the Death Ligand TRAIL , 2005, Neuron.

[145]  H. Lassmann,et al.  Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. , 2000, The American journal of pathology.

[146]  D. Bayliss,et al.  TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system. , 2009, Brain : a journal of neurology.

[147]  Richard Reynolds,et al.  HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage , 2009, Nature Neuroscience.

[148]  A. Compston,et al.  Multiple sclerosis. , 2002, Lancet.

[149]  E. Hogan,et al.  Increased calpain expression in activated glial and inflammatory cells in experimental allergic encephalomyelitis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[150]  Hans Lassmann,et al.  Cortical demyelination and diffuse white matter injury in multiple sclerosis. , 2005, Brain : a journal of neurology.

[151]  Gregory C Kujoth,et al.  Endurance exercise rescues progeroid aging and induces systemic mitochondrial rejuvenation in mtDNA mutator mice , 2011, Proceedings of the National Academy of Sciences.

[152]  Jens Frahm,et al.  Role of n‐type voltage‐dependent calcium channels in autoimmune optic neuritis , 2009, Annals of neurology.

[153]  Howard T. Jacobs,et al.  Premature ageing in mice expressing defective mitochondrial DNA polymerase , 2004, Nature.

[154]  T. Owens,et al.  Glutamate metabolism is down‐regulated in astrocytes during experimental allergic encephalomyelitis , 1997, Glia.

[155]  Hristian,et al.  RELAPSES AND PROGRESSION OF DISABILITY IN MULTIPLE SCLEROSIS , 2000 .

[156]  M. Beal,et al.  Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases , 2006, Nature.

[157]  Masahiko Watanabe,et al.  Altered expression of glutamate transporters in experimental autoimmune encephalomyelitis , 2002, Journal of Neuroimmunology.

[158]  W. Brück,et al.  BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? , 2002, Brain : a journal of neurology.

[159]  Arunesh Mittal,et al.  Casting light on multiple sclerosis heterogeneity: the role of HLA-DRB1 on spinal cord pathology. , 2013, Brain : a journal of neurology.

[160]  M. Esiri,et al.  Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. , 2004, Brain : a journal of neurology.

[161]  T. Olsson,et al.  Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis , 1996, Journal of the Neurological Sciences.

[162]  Stephen G Waxman,et al.  Co-localization of sodium channel Nav1.6 and the sodium-calcium exchanger at sites of axonal injury in the spinal cord in EAE. , 2004, Brain : a journal of neurology.

[163]  Jens Frahm,et al.  Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity , 2012, Nature.

[164]  M. Mattson,et al.  Recruiting adaptive cellular stress responses for successful brain ageing , 2012, Nature Reviews Neuroscience.

[165]  Hans Lassmann,et al.  Mitochondrial defects in acute multiple sclerosis lesions , 2008, Brain : a journal of neurology.

[166]  H. Neumann,et al.  Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. , 2010, Brain : a journal of neurology.